Pembrolizumab plus chemotherapy versus placebo plus chemotherapy in patients with advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) adenocarcinoma enrolled in the Republic of Korea: KEYNOTE-859.

被引：0
|
作者：
Rha, Sun Young
Lee, Jeeyun
Ryu, Min-Hee
Yin, Lina
Leconte, Pierre
Bhagia, Pooja
Oh, Do-Youn
机构：
[1] Yonsei Univ, Coll Med, Dept Internal Med, Div Med Oncol,Yonsei Canc Ctr, Seoul, South Korea
[2] Samsung Med Ctr, Seoul, South Korea
[3] Univ Ulsan, Coll Med, Asan Med Ctr, Seoul, South Korea
[4] Merck & Co Inc, Rahway, NJ USA
[5] MSD France, Puteaux La Defense, France
[6] Seoul Natl Univ, Coll Med, Seoul, South Korea
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2025年 / 43卷 / 4_SUPPL期
关键词：
D O I：
10.1200/JCO.2025.43.4_suppl.428
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：428 / 428
页数：1
相关论文
共 50 条
  • [1] Pembrolizumab plus chemotherapy for previously untreated, HER2-negative unresectable or metastatic advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: KEYNOTE-859.
    Tabernero, Josep
    Bang, Yung-Jue
    Van Cutsem, Eric
    Fuchs, Charles S.
    Janjigian, Yelena Y.
    Bhagia, Pooja
    Li Kan
    Adelberg, David E.
    Kui, Qin Shu
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [2] Q-TWiST analysis of pembrolizumab or placebo plus chemotherapy for patients with advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer in KEYNOTE-859.
    Wyrwicz, Lucjan
    Kalampoki, Vasiliki
    Valderrama, Adriana
    Ramakrishnan, Karthik
    Young, Kate
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL)
  • [3] Pembrolizumab or placebo plus chemotherapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: An updated analysis of KEYNOTE-859 for patients enrolled in Asia.
    Yen, Chia Jui
    Oh, Do-Youn
    Bai, Yuxian
    Ryu, Min-Hee
    Lee, Jeeyun
    Li, Jin
    Yang, Lin
    Yasui, Hisateru
    Yabusaki, Hiroshi
    Lam, Ka On
    Yamaguchi, Kensei
    Yeh, Kun-Huei
    Yin, Lina
    Leconte, Pierre
    Bhagia, Pooja
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 464 - 464
  • [4] KEYNOTE-859 update: Pembrolizumab plus chemotherapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer
    Ryu, M. H.
    Rha, S. Y.
    Wyrwicz, L. S.
    Weber, P. E. Yanez
    Bai, Y.
    Lee, J.
    Herrero, F. Rivera
    Alves, G. V.
    Garrido, M.
    Shiu, K-K.
    Gonzalez Fernandez, M.
    Li, J.
    Lowery, M. A.
    Cil, T.
    Cruz, F.
    Oh, D-Y.
    Yin, L.
    Bordia, S.
    Bhagia, P.
    Qin, S.
    ANNALS OF ONCOLOGY, 2024, 35 : S1473 - S1474
  • [5] Additional data from the KEYNOTE-859 study of pembrolizumab plus chemotherapy versus placebo plus chemotherapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer
    Wyrwicz, L.
    Oh, D.
    Weber, P.
    Bai, Y.
    Ryu, M.
    Lee, J.
    Rivera, F.
    Alves, G. Vasconcelos
    Garrido, M.
    Shiu, K.
    Fernandez, M. Gonzalez
    Li, J.
    Lowery, M.
    Cil, T.
    Cruz, F.
    Qin, S.
    Yin, L.
    Bordia, S.
    Bhagia, P.
    Rha, S.
    ANNALS OF ONCOLOGY, 2023, 34 : S181 - S181
  • [6] Pembrolizumab (Pembro) or placebo (Pbo) plus chemotherapy (Chemo) for advanced HER2-negative gastric/gastroesophageal junction (G/GEJ) adenocarcinoma (KEYNOTE-859): Asia subgroup analysis
    Oh, D-Y.
    Bai, Y.
    Ryu, M. H.
    Lee, J.
    Li, J.
    Luo, S.
    Pan, H.
    Qu, Y.
    Lu, J.
    Yang, L.
    Yasui, H.
    Yabusaki, H.
    Yen, C. J.
    Chan, W. W. L.
    Yamaguchi, K.
    Yeh, K-H.
    Yin, L.
    Bordia, S.
    Bhagia, P.
    Rha, S. Y.
    ANNALS OF ONCOLOGY, 2023, 34 : S1526 - S1526
  • [7] Pembrolizumab (pembro) plus chemotherapy (chemo) for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: Updated results from the KEYNOTE-859 study
    Rha, Sun Young
    Wyrwicz, Lucjan S.
    Weber, Patricio Eduardo Yanez
    Bai, Yuxian
    Ryu, Min-Hee
    Lee, Jeeyun
    Rivera, Fernando
    Alves, Gustavo Vasconcelos
    Garrido, Marcelo
    Shiu, Kai-Keen
    Fernandez, Manuel Gonzalez
    Li, Jin
    Lowery, Maeve Aine
    Cil, Timucin
    Cruz, Felipe Melo
    Oh, Do-Youn
    Yin, Lina
    Bordia, Sonal
    Bhagia, Pooja
    Qin, Shukui
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [8] A randomized, double-blind, phase III study of pembrolizumab plus chemotherapy as first-line therapy in patients with HER2-negative, advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: KEYNOTE-859
    Qin, S.
    Tabernero, J.
    van Cutsem, E.
    Fuchs, C. S.
    Janjigian, Y. Y.
    Bhagia, P.
    Li, K.
    Adelberg, D.
    Bang, Y-J.
    ANNALS OF ONCOLOGY, 2020, 31 : S1316 - S1317
  • [9] Pembrolizumab (pembro) plus chemotherapy (chemo) as first-line therapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: Phase III KEYNOTE-859 study
    Rha, S. Y.
    Wyrwicz, L. S.
    Weber, P. E. Y.
    Bai, Y.
    Ryu, M. H.
    Lee, J.
    Rivera, F.
    Alves, G. V.
    Garrido, M.
    Shiu, K. -k.
    Fernandez, M. Gonzalez
    Li, J.
    Lowery, M.
    Cil, T.
    Cruz, F. J. S. M.
    Qin, S.
    Yin, L.
    Bordia, S.
    Bhagia, P.
    Oh, D-y.
    ANNALS OF ONCOLOGY, 2023, 34 (03) : 319 - 320
  • [10] Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial
    Rha, Sun Young
    Oh, Do-Youn
    Yanez, Patricio
    Bai, Yuxian
    Ryu, Min-Hee
    Lee, Jeeyun
    Rivera, Fernando
    Alves, Gustavo Vasconcelos
    Garrido, Marcelo
    Shiu, Kai-Keen
    Fernandez, Manuel Gonzalez
    Li, Jin
    Lowery, Maeve A.
    Cil, Timucin
    Cruz, Felipe Melo
    Qin, Shukui
    Luo, Suxia
    Pan, Hongming
    Wainberg, Zev A.
    Yin, Lina
    Bordia, Sonal
    Bhagia, Pooja
    Wyrwicz, Lucjan S.
    LANCET ONCOLOGY, 2023, 24 (11): : 1181 - 1195
12345